Not true. As a mod, I checked. It meets the TOS as long as it is used in a PG 13 movie. Sometimes you gotta just roll with it. Lol...

No amount of offensive language will alter the value offered here...

Long...

I expect to see volatility until TD2 reports results of the study. Only those who know the true value of Cell in a Box(R) technology can see past the current PPS to the real potential here.

Long and Strong

"Stand for something, or fall for anything."

Very important and key points you have made here, highupside5. Thanks...

Thanks BioNewton. Managing by facts is key here as information can become very convuluted... :)

Phase 1 is intended to start third quarter of 2015.

"Studies of the effectiveness of PharmaCyte Biotech’s treatment in reducing the severe pain that accompanies advanced pancreatic cancer cannot be done in animals, but will require a human clinical trial. It is PharmaCyte Biotech’s plan that TD2 will conduct such a trial in the U.S in beginning in the third quarter of 2015."

http://www.pharmacytebiotech.com/research-development/

In February of 2015, TD2 started an extended study of the 2014 study in preparation for Phase 1 human trials.

SILVER SPRING, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a-Box(R) capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid.
“We are looking forward to the results of this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady,” commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
In the initial study, mice given an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups. There were 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech’s pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech’s pancreatic cancer treatment and cisplatin.
The follow-up study will use the same ES-2 ovarian cancer model. In this study, the mice will be divided into 13 different treatment groups, with 10 mice in each group. The follow-up study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon. The study will be conducted by Translational Drug Development (TD2) in the U.S. which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2.
The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it is painful and can cause breathing and other serious problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. PharmaCyte Biotech expects that its pancreatic cancer treatment will ultimately prove to be effective in slowing the accumulation of malignant ascites fluid and thus reduce the number of withdrawals of the fluid that patients must endure over a given period of time.

http://www.pharmacytebiotech.com/pharmacyte-biotech-initiates-expanded-follow-study-united-states-accumulation-malignant-ascites-fluid/

In December 2014, FDA grants ODD for pancreatc Cancer.

SILVER SPRING, MD, December 22, 2014 (GLOBE NEWSWIRE) – Nuvilex, Inc. (OTCQB: NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Nuvilex orphan drug designation for its pancreatic cancer treatment. Nuvilex’s pancreatic cancer treatment combines Nuvilex’s patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box®, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form. These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. This “targeted chemotherapy” has proven remarkably effective in past clinical trials.
“Receiving orphan drug designation by the FDA represents a significant milestone in the development of our pancreatic cancer treatment. This achievement is a very important one, both for Nuvilex and our partner Austrianova. It not only facilitates the future development of Nuvilex’s pancreatic cancer treatment, but also serves to validate the Cell-in-a-Box® technology.” stated Kenneth L. Waggoner, Chief Executive Officer of Nuvilex.
Nuvilex is currently preparing for a Phase 2b clinical trial in advanced pancreatic cancer (the orphan indication) in Australia to gain regulatory approval from agencies like the FDA for Nuvilex’s targeted chemotherapy of pancreatic cancer. Nuvilex’s clinical trial is planned to commence in 2015.
To access the FDA’s official listing of Nuvilex receiving the Orphan Drug Designation, use this link: http://www.accessdata.fda.gov/scripts/opdlisting/oopd/oopd_results_2.cfm?index_number=457014.
Orphan drug designation in the U.S. is given to drugs or treatments for “rare,” life-threatening diseases. In the U.S., a rare disease is defined as one that is diagnosed in less than 200,000 people in the U.S. In addition, in the U.S. pancreatic cancer can be classified as a life-threatening disease because, even with the best available chemotherapy, patients with advanced pancreatic cancer are destined to live less than one year on average and the 5-year survival rate is less than seven percent.
Receiving orphan drug designation for Nuvilex’s pancreatic cancer treatment carries with it up to 7 years of marketing exclusivity in the U.S. In addition, special assistance from the FDA in the development of Nuvilex’s treatment for pancreatic cancer and exemptions or reductions in regulatory fees and taxes can accompany the designation.

http://www.pharmacytebiotech.com/fda-grants-orphan-drug-designation-nuvilex-pancreatic-cancer-treatment/

In November 2014, results of preliminary study data was "remarkable".

SILVER SPRING, Md., Nov. 19, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage biotechnology company providing cell therapy solutions for the treatment of diseases, announced today that promising preliminary data has been released from the preclinical animal study on the effects of PharmaCyte Biotech’s pancreatic cancer treatment on the accumulation of ascites fluid in tumor-bearing animals. This study, performed by PharmaCyte Biotech contractor, Translational Drug Development (TD2), employed immunosuppressed mice implanted with disseminated human ovarian cancer cells into the peritoneal cavity.
Preliminary data analysis suggests that treatment with PharmaCyte Biotech’s live-cell encapsulation technology, Cell-in-a-Box(R) plus ifosfamide, produces a significant survival advantage as compared to non-treated control animals. PharmaCyte Biotech’s treatment appears to be at least as good as cisplatin, the current standard of care for ovarian cancer. However, when the encapsulated cells plus ifosfamide were used in conjunction with cisplatin, the survival rate was greatly enhanced. The final data analysis will be released in the future.
“The data itself is not only exciting from an ascites point of view, but also provides further evidence that encapsulated cells plus ifosfamide are effective at treating yet another type of malignant tumor. This provides the rationale for additional clinical trials of this novel therapy,” said Prof. Dr. Walter H. Gunzburg, the Chief Scientific Officer of PharmaCyte Biotech.
PharmaCyte Biotech CEO and President, Kenneth L. Waggoner, stated, “We couldn’t be more elated with the information we’re receiving from TD-2 as PharmaCyte Biotech’s preclinical studies progress. Based on the preliminary data we’ve received, PharmaCyte Biotech’s treatment appears to be performing admirably alone and remarkably as a combination treatment. This data justifies our decision last year to purchase the exclusive global rights to further develop Cell-in-a-Box(R) cancer treatments.”

http://www.pharmacytebiotech.com/nuvilex-announces-preliminary-data-preclinical-study-effects-pancreatic-cancer-treatment-ascites-fluid-formation/

The first preclinical studies at TD2 began in August of 2014.

SILVER SPRING, Md., Aug. 20, 2014 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (NVLX), a clinical-stage, international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that studies are underway at Translational Drug Development’s (TD2) facilities in Scottsdale, Arizona, to determine if PharmaCyte Biotech’s unique cancer treatment can slow the accumulation of fluid, known as “malignant ascites,” in the abdomen that is characteristic of the growth of many abdominal tumors.
Kenneth L. Waggoner, CEO and President of PharmaCyte Biotech, stated, “The start of these studies at TD2 is a banner day for PharmaCyte Biotech. We are extremely gratified to have a prestigious organization such as TD2 performing these studies on our behalf. It should be noted that these studies represent the first time that any work, either preclinical or clinical, has been done in the United States with the Cell-in-a-Box(R) cellulose-based live cell encapsulation technology that has such exciting potential.” Malignant ascites fluid in the abdomen contains cancer cells which can “seed” and form new tumors. Accumulation of this fluid is problematic for cancer patients and can cause significant discomfort. The current standard of care requires that malignant ascites fluid be removed from the abdomen of cancer patients at regular intervals.
In the studies being conducted by TD2, mice that have no immune system, and thus cannot reject foreign tissue from other species, will be injected with human ovarian cancer cells. These particular cells were chosen for these studies because: (i) they reproduce rapidly and form tumors; and (ii) the resultant tumors are proficient at producing malignant ascites fluid.
When the tumors have seeded in the abdomen, the mice will be randomized into four groups. One group of mice will be treated with PharmaCyte Biotech’s pancreatic cancer treatment consisting of the combination of Cell-in-a-Box(R) encapsulated live cells and the cancer prodrug ifosfamide (the encapsulated cells express an enzyme, CYP2B1, which converts ifosfamide into its cancer-killing form). A second group of mice will be treated with a drug normally used to treat ovarian cancer, and a third group will be administered that drug along with PharmaCyte Biotech’s Cell-in-a-Box(R) encapsulated live cells and ifosfamide combination. The remaining mice will serve as the “control” group for comparison purposes. The mice will be followed until humane endpoints have been reached. The time for this to occur for the treated mice will be compared to that for the control group of mice.
PharmaCyte Biotech’s CEO and President added, “We are confident that this work at TD2 will prove to be just the beginning of a long and fruitful journey for PharmaCyte Biotech as we strive to develop our unique cancer treatment.”

http://www.pharmacytebiotech.com/nuvilex-begins-preclinical-studies-translational-drug-development-determine-nuvilexs-unique-cancer-treatment-can-slow-accumulation-malignant-ascites-fluid/

Very nice post techi and a keeper for sure. Thank you, your DD is always outstanding. I think it says a lot about PharmaCyte to have SOOO many intelligent people investing here for the long term...

Long and Strong...

I think some are getting very nervous about all the power we have, the least of which is the technology itself. Dr Von Hoff, who probably knows the most about inoperable pancreatic cancer treatments available, came to PMCB to get involved with a study for pain and ascites associated with all abdomal cancers.

Now, we are doing an extension of that study. I believe big Pharma will be interested if not already. Wish I had more of an idea on the CTO. The fact that there is one makes me think there may be much more going on behind the scenes...

:)

Ken Waggoner is a very hands on CEO and an attorney. If he was not above the board, he would not be responding directly to shareholders himself. I like him as our CEO and have total faith in his abilities. He has achieved numerous milestones since coming aboard.

Stay focused longs... Ken explained why no one has been to the office. I like that they have been traveling working for this technology to get to market. It's easy to lose focus while waiting on study results...

"Stand for something, or fall for anything..."

Good to hear Pete. I especially like the R&D addition to the website. This is an important section to have for any biotech company. As I have said before, I think our executives are doing a great job. They are focused on all the right things, imo.

http://www.pharmacytebiotech.com/research-development/

Thanks Pete... I hope your travels are going well and I am glad you are able to still keep in touch... :)

Now that was a responsible approach to resolve this issue. I was never concerned and know that we have minimal staff with lots of irons in the fire but thank you so much for taking the time to do this and sharing the response you received. I have contacted Ken W on a couple of occasions on LinkedIn just to thank him for all he has done. I am no one important and yet he always responds with a nice timely comment.

Long and Strong...

Great video at the bottom of this article that talks about Dr Von Hoff and team's approach to finding a treatment to improve the one year survival rate for those diagnosed with pancreatic cancer...

http://www.standup2cancer.org/dream_teams/view/cutting_the_fuel_supply_a_new_approach_to_the_treatment_of_pancreatic_cance

Thanks BioNewton. It's important to keep our eye on the target and it helps to remember what we hold...

Cell in a Box technology is potentially revolutionary in that it's unique composition sets it apart from all other such devices.

It can be used with many different prodrugs and everything we know from past trials and recent studies tells us that using CiaB technology with currently approved drugs enhances the treatment and reduces toxicity. The drugs are put in CiaB and then implanted near the tumor or area to be treated.

Here is a great post from one of our Longs, rudygerner, that explains the technology in more detail...

"This is why Nuvilex and it's proprietary cellulose-based live-cell encapsulation is the future of cancer and diabetes treatments:

Capsules composed of cellulose sulphate and polydimethyldiallyl ammonium have excellent mechanical properties and can be manufactured to consistent diameter and pore size.

The encapsulated cells can be cultivated in a normal cell culture medium (the nature of which depends on the encapsulated cells) at standard conditions of humidity, temperature and CO2 concentration. During this culture period production of antibodies from the capsules into the cell culture medium can be demonstrated with either Western Blot or Elisa technology using specific antigens and can furtheron be quantitated using second antibodies conjugated to fluorogenic dyes.

After a suitable period in culture (normally not less than 1 hour and not exceeding 30 days), the cell containing capsules can be surgically implanted either directly, or by injection using a syringe into various areas of the body.

The antibodies produced by the encapsulated cells according to the invention can be based on any immunglobulin class useful for therapy, including but not limited to genetically modified antibodies.

The encapsulated cells according to the invention can be cells taken from patients or from any other source, including human and animal cells, that have been genetically modified for the production of cloned antibodies.

The encapsulated cells and capsules, respectively, are especially used for the implantation into a living animal body, including a human, for the treatment of diseases or disorders responsive to the antibodies released from said capsules. After implantation of capsules into an animal body intraperitoneally and subcutaneously it has been found that the capsules, especially cellulose sulphate capsules, offer an obvious advantage with respect to mechanical resistance over, for instance, alginate capsules since there are found intact as long as 10 months post-implantation regardless of whether they are implanted subcutaneously or intraperitoneally.

Additionally, it has been observed that subcutaneous and intraperitoneal implantations of cell-containing cellulose sulphate capsules revealed differences with respect to at least two points. First, the amount of antibody released in the bloodstream was markedly higher in the former situation. A very likely explanation for this difference resides in the fact that capsules are rapidly vascularized when implanted subcutaneously and are not vascularized at all when implanted intraperitoneally. The beneficial effect of vascularization might be two-fold, firstly facilitating antibody uptake by blood and, secondly, ensuring a better supply of nutrients favoring cell survival since viability of cells within intraperitoneally implanted capsules was reproducibly observed to be lower. In addition to extensive vascularization, which showed no significant alteration over the 10 months of the follow-up, the clustering of cells within a connective pouch after subcutaneous implantation would allow removal of capsules through an easy onestep surgical ablation of the whole neorgan should this prove necessary. Finally, it is important to underline that development of isolating fibrosis around implanted cellulose sulphate capsules is not systematic. This observation contrasts with what has been reported in the case of alginate-poly(L)-alginate microcapsules around which a host reaction with fibrosis developed probably as a result of potent macrophage activation by the encapsulating polymer (Pueyo, M. E, et al., J. Biomater Sci. Polym. Ed., Vol. 5, 197-203 (1993))."

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102458582

Good one... :)

Three U.S. Senators cross party lines to introduce bipartisan legislation that would help those who rely on medicinal marijuana.

Sen. Cory Booker (D-NJ), Sen. Rand Paul (R-KY) and Sen. Kirsten Gillibrand (D-NY) introduced a bill to allow patients and doctors in states that have legalized medicinal marijuana laws to participate in those programs without fear of federal prosecution.

“Today we join together to say enough is enough,” said Sen. Booker. “Our federal government has long overstepped the boundaries of common sense, fiscal prudence, and compassion with its marijuana laws. These laws must change.”

The legislation, dubbed CARERS Act (Compassionate Access, Research Expansion, and Respect States), would change marijuana’s classification from Schedule I to Schedule II.

“Schedule II, the definition is the drug has a high potential for abuse, but the drug has a currently accepted medical use and treatment in the United States,” explains Sen. Gillibrand. “You have to look at this the same way that opiates are. They’re a powerful drug, but they are going to be used for medical uses. The drug can be prescribed.”

Medicinal marijuana is now legal in 23 states and the District of Columbia, while marijuana oil extract is permitted in 12 states to treat symptoms such as epileptic seizures, especially in children. But lawmakers in states where marijuana oil is legal are still facing an uphill battle to make the treatment more accessible to patients.

Just last week in Iowa, State Sen. Joe Bolkcom introduced a bill to allow better access to highly-regulated production and distribution of medicinal marijuana. The issue isn’t allowing patients to receive the treatment…but rather being able to provide the treatment in the first place. Iowa’s marijuana oil law was passed in 2014 by Gov. Terry Branstad, but critics tell the Des Moines Register “the law is practically useless.” The official cards issued in Iowa alert police that carriers have the legal right to possess the extract, but the program does not offer legal means to obtain the medicine. The new legislation introduced by Booker, Gillibrand and Paul would hopefully change that.

“There is every reason to give more ease to people in states who want this,” said Sen. Paul. “Doctors can prescribe this more easily…it has great potential for research.”

http://www.msnbc.com/hardball/bipartisan-bill-introduced-medicinal-marijuana-0

Good to see you... :)

Treatment of Insulin-Dependent Diabetes


Since the year 2000, efforts have been made to develop treatments for Type 1 diabetes that do not involve multiple daily injections of insulin to control the blood sugar levels of individuals suffering from this disease. In individuals with Type 1 disease, the islet cells of the pancreas cannot produce the insulin required to control blood sugar levels and thus, such individuals can suffer the serious and debilitating consequences of the disease which include peripheral nerve damage, damage to the retinas of the eyes, kidney problems and cardiac damage. Initially, “naked” pancreatic islet cells were transplanted into humans with Type 1 diabetes, but these cells were soon destroyed by the body’s immune system.
To avoid such immune system damage, islet cells from humans and from pigs have been encapsulated before implantation. However, the success of this approach is somewhat limited because the encapsulation material used in such studies is agarose, a derivative of seaweed. Compared to PharmaCyte Biotech’s cellulose-based capsules, agarose-based capsules have a rather limited lifetime in the body and need to be replaced, and the insulin-producing capacity of the islet cells within such capsules is difficult to maintain. In addition, the use and/or supply of human or pig islet cells can be problematic.
PharmaCyte Biotech has approached these problems by deciding to use the Cell-in-a-Box® technology to encapsulate insulin-producing cells that are not pancreatic islet cells but rather transformed human cells. For PharmaCyte Biotech’s initial efforts to develop a treatment for Type 1 diabetes, it has obtained the rights to a human, non-pancreatic cell line developed by researchers in Australia. Preclinical studies have been designed to test these cells, after encapsulation using the Cell-in-a-Box® technology, for their ability to produce insulin “on demand” under a variety of conditions, as well as to fulfill other criteria that will be required before they can be used in humans; these studies are in progress. In the event that these cells are not acceptable for use, attempts will be made to develop an insulin-producing cell line that meets all of the requirements for encapsulation and then used in clinical trials in humans.
To facilitate all of the studies that will be needed before clinical trials can be undertaken. PharmaCyte Biotech has formed a Diabetes Consortium that will include prominent investigators from institutions in several countries. Participants in the Diabetes Consortium will be involved in all phases of the development of PharmaCyte Biotech’s treatment for Type 1 diabetes.

http://www.pharmacytebiotech.com/research-development/

This study is key here. Already have our sight set on Phase 1 to start in third quarter following these study results.

PharmaCyte Biotech Initiates Expanded Follow-up Study in the United States on the Accumulation of Malignant Ascites Fluid

SILVER SPRING, Md., Feb. 19, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced the commencement of an expanded, follow-up study of the effectiveness of its pancreatic cancer treatment (a combination of low doses of the cancer prodrug ifosfamide and Cell-in-a-Box(R) capsules containing live cells capable of converting ifosfamide into its cancer-killing form) on the accumulation of malignant ascites fluid.
“We are looking forward to the results of this expanded preclinical study of the effectiveness of our pancreatic cancer treatment in reducing the rate of malignant ascites fluid accumulation in the abdomen. If successful, it could quickly lead to a clinical trial in patients with abdominal tumors who suffer from this very serious cancer-associated malady,” commented Kenneth L. Waggoner, Chief Executive Officer of PharmaCyte Biotech.
In the initial study, mice given an aggressive human ovarian cancer (ES-2), which produces significant amounts of malignant ascites fluid, were divided into 4 groups. There were 10 mice in each group. The mice in Group 1 served as a control group. Group 2 was made up of mice treated with PharmaCyte Biotech’s pancreatic cancer treatment. Group 3 was treated with cisplatin, a chemotherapy drug often used to treat ovarian cancer. Group 4 was treated with a combination of PharmaCyte Biotech’s pancreatic cancer treatment and cisplatin.
The follow-up study will use the same ES-2 ovarian cancer model. In this study, the mice will be divided into 13 different treatment groups, with 10 mice in each group. The follow-up study is designed to better define the parameters that will be needed to design a future Phase 1 clinical trial in humans that suffer from malignant ascites fluid accumulation as a result of their abdominal cancers, such as pancreatic, liver, ovarian, uterine and colon. The study will be conducted by Translational Drug Development (TD2) in the U.S. which was designed by pancreatic cancer expert Dr. Daniel D. Von Hoff, Chief Development Officer of TD2.
The accumulation of ascites fluid is problematic for patients with an abdominal cancer because it is painful and can cause breathing and other serious problems. Once it gets to a certain stage, it must be removed on a regular basis. This procedure in itself is very uncomfortable for patients and costly. PharmaCyte Biotech expects that its pancreatic cancer treatment will ultimately prove to be effective in slowing the accumulation of malignant ascites fluid and thus reduce the number of withdrawals of the fluid that patients must endure over a given period of time.

"Studies of the effectiveness of PharmaCyte Biotech’s treatment in reducing the severe pain that accompanies advanced pancreatic cancer cannot be done in animals, but will require a human clinical trial. It is PharmaCyte Biotech’s plan that TD2 will conduct such a trial in the U.S in beginning in the third quarter of 2015."

http://www.pharmacytebiotech.com/research-development/
http://www.pharmacytebiotech.com/pharmacyte-biotech-initiates-expanded-follow-study-united-states-accumulation-malignant-ascites-fluid/

ODD received for Pancreatic Cancer within Ken Waggoner's first year with PharmaCyte. I am very impressed with all he has been able to accomplish in his 18 months with the company.

Additionally, we have begun preclinical studies for diabetes and for malignant ascites. As a shareholder, I am glad Ken decided to help get CiaB to market.


"In December 2014, the FDA granted PharmaCyte Biotech orphan drug designation for its pancreatic cancer treatment. Orphan drug designation in the U.S. is given to drugs or treatments for “rare,” life-threatening diseases. In the U.S., a rare disease is defined as one that is diagnosed in less than 200,000 people in the U.S. In the U.S., pancreatic cancer can be classified as a life-threatening disease because, even with the best available chemotherapy, patients with advanced pancreatic cancer are destined to live less than one year on average and the 5-year survival rate is less than seven percent.
Receiving orphan drug designation for PharmaCyte Biotech’s pancreatic cancer treatment carries with it up to 7 years of marketing exclusivity in the U.S. In addition, special assistance from the FDA in the development of the Company’s treatment for pancreatic cancer and exemptions or reductions in regulatory fees and taxes can accompany the designation."

http://160.153.35.100/pancreatic-cancer/

http://160.153.35.100/research-development/

This post is a keeper for me as this does come up quite a bit. Thanks, Bill.

From the new website's R&D page...

PharmaCyte Biotech’s pancreatic cancer treatment will also be used to determine if it can alleviate the pain and ascites fluid accumulation that occurs in patients with advanced pancreatic cancer. Translational Drug Development (TD2), a premier oncology CRO in the U.S., has been contracted to carry out preclinical and clinical studies in these areas. The first preclinical study has shown evidence that PharmaCyte Biotech’s treatment may be effective in delaying the accumulation of ascites fluid in mice bearing an aggressive form of ovarian cancer. A follow-up study is being done to better define the parameters by which PharmaCyte Biotech’s pancreatic cancer treatment can delay the accumulation of ascites fluid. If successful, this expanded study could lead to clinical trials in humans. Studies of the effectiveness of PharmaCyte Biotech’s treatment in reducing the severe pain that accompanies advanced pancreatic cancer cannot be done in animals, but will require a human clinical trial. It is PharmaCyte Biotech’s plan that TD2 will conduct such a trial in the U.S in beginning in the third quarter of 2015.

http://pharmacytebiotech.com/research-development/

Nice comparison bill considering the differences in share structure and business model. Good to see you back... :)

Hey Otsy, the expanded study is using 13 different treatments, I wonder if they could be testing CiaB with one or more of these drugs developed from the Thundergod Vine...

I think that folks forget how valuable is this technology. We are not the drug, we are the targeted delivery system that can take many prodrugs directly to the site of the tumor. Dr Von Hoff was interested in this technology for a reason. We will know soon enough as Deborah said. :)

Go get 'em Pistol Pete and take care...

New clinical studies... Both started this quarter...

http://www.firstwordmedtech.com/node/973245

http://www.nuvilex.com/latest-news/155-pharmacyte-biotech-initiates-first-preclinical-study-of-its-encapsulated-cell-product-for-novel-treatment-of-diabetes

Very nice post, Newbigtech...

Well put and puts everything in the proper perspective...

It is Cell-in-a-Box(R)'s time now as we will soon know for certainty when we hear about the extended study with TD2 and the subsequent Phase 1.

I had no doubt about the certainty of this technology when we heard the first study went very well. At that time we knew we performed better than current treatments just as we had done in the past.

Thanks

http://www.nasdaq.com/press-release/pharmacyte-biotechs-expanded-followup-study-on-malignant-ascites-fluid-accumulation-in-final-stage-20150126-00537

http://www.cancer-therapy.org/CT/v1/A/13%20%20L%C3%B6hr%20et%20al,%20121-131%20cop.pdf

Nice post thorbus...

I use to think it was them too until I noticed how much damage they do and how they are used to put the company in a bad light. All the guys at PMCB are very professional and we have an IR company we do pay. We disclose every other PR for which we pay, like those from Stock Market Media Group. I just don't see why, in the case of Cream Consulting, there would be secrecy around who is paying. Manipulators rely on the average investor being easily duped... I am just reading between the lines.

Read this article in full Bill. This info started making me think about the lengths to which some may go to try and put PMCB in a negative light. With us being an unknown in the investment world, we are and have been an easy target. That will all change soon, imo.

http://ajrarchive.org/Article.asp?id=4911

Who is Cream Consulting? I don't believe PMCB has a relationship with them. We certainly don't benefit by such tactics as spam emails. We are pretty transparent. Cream Consulting is covert. Could it be that someone pays for these to make the company appear to be a pump and dump?

If that were true, there would be no longs. I know hundreds... We believe in the technology and are not persuaded by tactics which are put into play to make it appear that this is not a valuable investment, long term.

Some peole are visionary and can see past what some see as a permanent circumstance.

I can look right past this pps to the future pps which reflects the value of CiaB technology... Proof is imminent... We can wait...

Here are a few significant words from these world-renowned doctors...

Doctors Lohr, Gunzburg and Salmons refer to Cell in a Box(R) technology as "magic bullets of the 21st century". Dr Lohr is now leading our SAB and Dr Gunzburg is now our CSO.

Doctor Crabtree is our COO and he knows Dr Von Hoff well. They are most definitely peers.

"The Nuvilex team presents us with a new tool to employ against the symptoms and invasive properties of this very challenging cancer," said Daniel D. Von Hoff, M.D., Chief Development Officer of TD2. "Our Pancreatic Cancer Research Team (PCRT) colleagues are enthusiastic to begin clinical trials with this approach."

http://www.td2inc.com/news/nuvilex-selects-translational-drug-development-td2-to-advanc

http://www.marketwatch.com/story/nuvilex-incs-cell-in-a-box-treatment-called-magic-bullets-of-21st-century-by-world-renowned-oncologist-2014-05-05

http://www.ncbi.nlm.nih.gov/pubmed/12042985

http://publicationslist.org/maloehr

http://www.nuvilex.com/management

I think most longs have other avenues of communicating with one another. This forum is primarily for traders. Some longs come and post occasionally which is great to see. But for the most part, we are just waiting to hear on study results and upcoming trials...

As some may hope, the hundreds of longs I know are not leaving the building. Maybe traders are as it appears their pump and dump efforts are failing...

Patent protection

http://www.faqs.org/patents/assignee/austrianova-singapore-pte-ltd/

I don't imagine this has changed much since any of us has purchased this stock. If we weren't concerned when we purchased, why would be suddenly be concerned?

We know this is a start-up biotech and most longs purchased for the technology, not strong financials... :)

We believe the financial strength is to come with the proven technology.

Bios take time. Patience is important if you want to see it through. I do...

With no real buyers, the PPS is controlled by MMs. It is as simple as that. Until we get trial results, it will continue on this path...

The studies are underway for both malignant ascites and diabetes. The science will be the only thing that will effect the pps.

Holding long for the treatment that may change lives...

Patience is Key to Investing

Patience Minimizes Risk

"The longer money can remain invested the more potential for minimizing the impact of a down market. If time is on your side, it is not necessary to sell an investment when the value has gone down. A patient investor understands the value of staying invested to allow the market to recover. Long-term success comes not by reading the daily financial headlines, but by being patient and sticking to the designed plan."

I believe this is especially true for PharmaCyte. Seriously, things could change overnight. Those who are invested know how valuable is Cell in a Box(R) technology. So does Big Pharma. Have no doubt!

http://www.insideindianabusiness.com/contributors.asp?id=2492